Arthur D. Little - information for the media

Welcome to the press section of Arthur D. Little. We put great emphasis on good relations with the media. In the press section, you will find the latest press releases, contact partners and our media echo showing you the most important publications in different countries. We would like to expressly invite the media to contact us if you have additional enquiries or need particular information.

Latest press releases

Healthcare UK, London - 30 August 2017

A model fund

Today’s clinical trial costs can cost biopharma companies upwards of $100mn  before they even begin to consider additional investment in the marketing and distribution mechanisms that will deliver new life enhancing therapies to patients. For those major drug companies that spent the last decade building a robust pipeline of early stage compounds and indications, these sky-high development costs mean they have a wide portfolio of potential assets without the resources to get them through trial phase. The result? Pharmaceutical businesses with strong R&D pipelines are losing billions each year in potential revenue while promising new therapies sit dormant, waiting for their patents to expire. In this article, Ben van der Schaaf at Arthur D. Little, gives a five-step guide to explore possible funding partnerships for lower-priority drug trials — a new model for big pharma.

Notes to Editors

European Pharmaceutical Manufacturer

Search by keyword

Marketing & Communication Director

Francois Valraud
Chief Operating Officer
Arthur D. Little Services

+33 1 55 74 29 20

Article Toolbar

Navigation« previous article|next article »


| |Bookmark Arthur D. Little